Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity by Josie, Parker & Steven, Kelly
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
mBio
                          
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa40336
_____________________________________________________________
 
Paper:
Luna-Tapia, A., Willems, H., Parker, J., Tournu, H., Barker, K., Nishimoto, A., Rogers, P., Kelly, S., Peters, B. et. al.
(2018).  Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without
Compromising Candida albicans Pathogenicity. mBio, 9(3), e00225-18
http://dx.doi.org/10.1128/mBio.00225-18
 
 
 
 
 
 
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International
license.
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 Loss of Upc2p-Inducible ERG3 Transcription Is Sufﬁcient To
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ABSTRACT Inactivation of sterol Δ5,6-desaturase (Erg3p) in the prevalent fungal
pathogen Candida albicans is one of several mechanisms that can confer resistance
to the azole antifungal drugs. However, loss of Erg3p activity is also associated with
deﬁciencies in stress tolerance, invasive hyphal growth, and attenuated virulence in
a mouse model of disseminated infection. This may explain why relatively few erg3-
deﬁcient strains have been reported among azole-resistant clinical isolates. In this
study, we examined the consequences of Erg3p inactivation upon C. albicans patho-
genicity and azole susceptibility in mouse models of mucosal and disseminated in-
fection. While a C. albicans erg3Δ/Δ mutant was unable to cause lethality in the dis-
seminated model, it induced pathology in a mouse model of vaginal infection. The
erg3Δ/Δ mutant was also more resistant to ﬂuconazole treatment than the wild type
in both models of infection. Thus, complete loss of Erg3p activity confers azole resis-
tance but also niche-speciﬁc virulence deﬁciencies. Serendipitously, we discovered
that loss of azole-inducible ERG3 transcription (rather than complete inactivation) is
sufﬁcient to confer in vitro ﬂuconazole resistance, without compromising C. albicans
stress tolerance, hyphal growth, or pathogenicity in either mouse model. It is also
sufﬁcient to confer ﬂuconazole resistance in the mouse vaginal model, but not in
the disseminated model of infection, and thus confers niche-speciﬁc azole resistance
without compromising C. albicans pathogenicity at either site. Collectively, these re-
sults establish that modulating Erg3p expression or activity can have niche-speciﬁc
consequences on both C. albicans pathogenicity and azole resistance.
IMPORTANCE While conferring resistance to the azole antifungals in vitro, loss of
sterol Δ5,6-desaturase (Erg3p) activity has also been shown to reduce C. albicans
pathogenicity. Accordingly, it has been presumed that this mechanism may not be
signiﬁcant in the clinical setting. The results presented here challenge this assump-
tion, revealing a more complex relationship between Erg3p activity, azole resistance,
C. albicans pathogenicity, and the speciﬁc site of infection. Most importantly, we
have shown that even modest changes in ERG3 transcription are sufﬁcient to confer
azole resistance without compromising C. albicans ﬁtness or pathogenicity. Given that
previous efforts to assess the importance of ERG3 as a determinant of clinical
azole resistance have focused almost exclusively on detecting null mutants, its
role may have been grossly underestimated. On the basis of our results, a more
thorough investigation of the contribution of the ERG3 gene to azole resistance
in the clinical setting is warranted.
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Mortality rates associated with invasive fungal infections (IFIs) remain alarminglyhigh, despite the availability of three major classes of antifungal drugs (1). One of
the most prevalent fungal pathogens, Candida albicans, is estimated to cause more
than 400,000 IFIs annually, with attributable mortality rates of 35 to 75% (2). Candida
species are also a leading cause of mucosal disease, including a collection of oral
manifestations (3), and vaginal candidiasis, which afﬂicts 70 to 75% of healthy adult
women (4). Aside from episodic infections, 5 to 10% of all women suffer from recurrent
vulvovaginal Candida infections that cause chronic vaginal pain and require long-term
antifungal maintenance therapy to alleviate symptoms (4). Improving patient outcomes
for both disseminated and mucosal infections will depend upon a detailed understand-
ing of the causes of treatment failure and the development of countermeasures. The
azole antifungals remain the most widely used therapies, acting through inhibition of
lanosterol demethylase (Erg11p), an enzyme involved in ergosterol biosynthesis. The
resulting depletion of cellular ergosterol and the accumulation of abnormal sterol
species, such as 14-methylergosta-8,24(28)-dien-3,6-diol, are both thought to
cause plasma membrane dysfunction, ultimately leading to growth arrest (5). Several
acquired mechanisms of azole resistance have been characterized in C. albicans, and
these mechanisms include overexpression of drug efﬂux pumps belonging to the major
facilitator and ABC transporter superfamilies, as well as the target enzyme itself (6, 7).
Mutations that alter the target enzymes’ (Erg11p) azole binding afﬁnity are also
important determinants of susceptibility (8–10). However, a combination of the above
mechanisms are usually necessary to confer clinically relevant levels of azole resistance
(7, 11–13). Notably, the resistance of many fungal isolates is not fully accounted by
these mechanisms (14).
An alternative mechanism of azole resistance can arise through inactivation of sterol
Δ5,6-desaturase (Erg3p), the enzyme responsible for converting 14-methylfecosterol,
which accumulates upon azole-mediated inhibition of Erg11p, into the dysfunctional
diol species (5). However, while azole-resistant mutants devoid of Erg3p activity can be
readily selected in vitro (15), only a handful have been reported among azole-resistant
clinical isolates of C. albicans (5, 16–18). This may be because loss of Erg3p activity itself
blocks a late step of ergosterol biosynthesis (17), resulting in membrane abnormalities
and hypersensitivity to some physiological stresses (19–22). In C. albicans, loss of Erg3p
activity has also been associated with defects in hyphal growth (17, 20, 23), a major
virulence determinant of this species (24, 25). Accordingly, several reports have de-
scribed both clinically derived and lab-engineered erg3 mutants as having attenuated
virulence in a mouse model of hematogenously disseminated infection (18, 20, 23).
Thus, while inactivation of Erg3p leads to azole resistance, the associated ﬁtness and
pathogenicity defects may disfavor the selection of erg3 mutants in the clinical setting.
The signiﬁcance of ERG3 inactivating mutations to azole resistance in the clinical setting
has been further brought into question by the ﬁnding that a C. albicans erg3/mutant
is susceptible to azole treatment in a mouse model of disseminated infection, despite
in vitro resistance (23). Either way, to date, the consequences of Erg3p inactivation upon
C. albicans pathogenicity and azole resistance at mucosal body sites has not been
directly tested. This is important, as we previously reported that C. albicans erg2/ and
erg24/ ergosterol biosynthetic mutants (lacking C-8 sterol isomerase and C-14 sterol
reductase, respectively), are essentially avirulent in the disseminated model but readily
colonize the mouse vagina (26).
The purpose of this study was to determine how loss of Erg3p activity affects
C. albicans pathogenicity and azole resistance in a mouse model of vaginal candidiasis.
In the course of conducting these studies, we serendipitously discovered that altering
the regulation of ERG3 transcription is sufﬁcient to induce in vitro and niche-speciﬁc in
vivo azole resistance, without compromising the pathogenic ﬁtness of the fungus.
RESULTS
Altering ERG3 transcription is sufﬁcient to induce in vitro azole resistance
without compromising Candida albicans ﬁtness. To determine whether the loss of
Luna-Tapia et al. ®
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Erg3p activity affects C. albicans pathogenicity and azole resistance in a murine model
of vaginal candidiasis, we ﬁrst constructed a C. albicans erg3/ deletion strain using
a PCR-based approach (27). A reconstituted strain was then made by reintroducing a
wild-type ERG3 allele, including 582 bp of 5= untranslated region (5= UTR) and 303 bp
of 3= UTR into the deletion strain using an integrating vector that fully restores the
IRO1-URA3 locus (28) to circumvent the well-documented positional effects of URA3
integration (29). A prototrophic (and isogenic) deletion strain was produced by intro-
ducing the vector alone into the erg3/ mutant.
To conﬁrm the expected in vitro azole resistance of the erg3/ strain, we tested its
susceptibility to ﬂuconazole using the standard CLSI broth microdilution protocol (30).
As anticipated, the erg3/ mutant was insensitive to ﬂuconazole (Fig. 1). Unexpect-
edly, the ERG3 reconstituted strain (from here on referred to as shprERG3 [shpr stands
for shorter promoter]), was also fully resistant to ﬂuconazole (Fig. 1), voriconazole (see
Fig. S1A in the supplemental material), itraconazole (Fig. S1B), and ketoconazole
(Fig. S1C). This result was conﬁrmed by testing multiple independently constructed
strains of the same genotype. Sequence analysis conﬁrmed the absence of mutations
within the cloned ERG3 sequences. Subsequently, a second ERG3 reconstituted strain
(from here on referred to as lnprERG3 [lnpr stands for longer promoter]) was produced
by reintroducing ERG3 with 1,000 bp of the 5= UTR, which was sufﬁcient to restore
ﬂuconazole susceptibility (Fig. 1). These results initially suggested that insufﬁcient 5=
UTR had been reintroduced into the shprERG3 strain and that some promoter element
FIG 1 The 5= UTR of ERG3 is an important determinant of C. albicans azole susceptibility. The C. albicans
erg3Δ/Δ mutant was complemented by reintroduction of a wild-type copy of the ERG3 ORF with either
582 nucleotides (nt) (strain shprERG3) or 1,000 nt (strain lnprERG3) of the 5= UTR and 303 nt of the 3= UTR.
The ﬂuconazole susceptibility of the wild-type (WT), erg3Δ/Δ, shprERG3, and lnprERG3 strains and an
azole-resistant clinical isolate (TW17) was evaluated using the standard CLSI broth microdilution protocol.
Following 24 h (A) or 48 h (B) of incubation, growth was measured as OD600 and expressed as a
percentage of the growth in the control wells with no drug (DMSO alone) for each strain. The means 
standard deviations (error bars) for three biological replicates are indicated.
ERG3, Azole Resistance, and C. albicans Pathogenicity ®
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essential for ERG3 transcription lies between 1,000 and 582 bp upstream of the start
codon. Surprisingly, this was not supported by quantitative reverse transcription-PCR
(qRT-PCR) analysis, which revealed similar levels of the ERG3 transcript in wild-type,
shprERG3, and lnprERG3 strains (Fig. 2). However, while the addition of 5 g/ml
ﬂuconazole increased the ERG3 transcript three- to fourfold in both wild-type and
lnprERG3 strains, this response was not observed in the shprERG3 strain. As expected,
no ERG3 transcript was detected in the erg3/ strain.
Given that the shprERG3 strain expresses apparently normal levels of the ERG3
transcript in the absence of the azoles, we next examined several other phenotypes
that have been associated with Erg3p deﬁciency (22, 31). The erg3/ mutant was
hypersensitive to membrane stress caused by the detergent SDS, as well as ionic
stresses induced by high concentrations of CaCl2 or NaCl (Fig. 3A). However, these
phenotypes were not observed in either the shprERG3 or lnprERG3 strains, which
behaved as the wild-type control.
Several C. albicans Erg3p-deﬁcient strains have also been described as having
defects in hyphal growth (17, 18, 20, 23), which is essential for pathogenicity (24, 25).
Similarly, we found our erg3Δ/Δ mutant to be deﬁcient in hyphal growth on medium
199 (M199) and 10% fetal bovine serum (FBS) agar (Fig. 3B). Under these conditions,
both the shprERG3 and lnprERG3 strains formed apparently normal hyphae. Notably,
the C. albicans erg3Δ/Δ mutant can form hyphae when grown in liquid M199 medium
at 37°C (Fig. S2) or when Ume6p, a transcription factor that activates the expression of
hypha-speciﬁc genes, is overexpressed (Fig. S3). Thus, the C. albicans erg3Δ/Δ mutant
is capable of forming hyphae under at least some conditions. As hyphal growth is
intimately linked to the ability of C. albicans to form bioﬁlms (32), we compared each
strain’s capacity to produce bioﬁlms using a simple in vitro assay. While the erg3/
mutant has diminished capacity to form bioﬁlms, both shprERG3 and lnprERG3 strains
were unaffected (Fig. 3C).
In summary, reintroducing ERG3 with the shorter promoter into the erg3/ strain
is sufﬁcient to restore normal stress tolerance and hyphal growth but insufﬁcient
to confer in vitro ﬂuconazole susceptibility. The phenotypes of the shprERG3 strain
demonstrate that reducing ERG3 transcription or eliminating its azole-inducible expres-
sion (rather than complete loss of Erg3p function) is sufﬁcient to dramatically enhance
C. albicans survival following azole exposure, and without compromising fungal ﬁtness
or virulence-related attributes.
Azole-induced ERG3 transcription is dependent upon the Upc2p transcription
factor. To provide a convenient reporter of transcriptional activity, either 582 bp (short
FIG 2 Azole-inducible ERG3 transcription is lost in the shprERG3 strain. Wild-type (WT), erg3Δ/Δ,
shprERG3, and lnprERG3 strains were grown for 24 h in YPD at 37°C in the presence or absence of 5
g/ml ﬂuconazole. RNA was then extracted, ERG3 transcript abundance was quantiﬁed by qRT-PCR using
the ΔCT method, and ERG3 transcript levels were normalized to that of ACT1. The mean plus standard
error of the mean (error bar) for three biological replicates are shown for each strain. Each treatment
group was compared using a two-way analysis of variance (ANOVA) and Tukey’s multiple-comparison
test, and the P values are indicated.
Luna-Tapia et al. ®
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promoter) or 1,000 bp (long promoter) of the ERG3 5= UTR was ampliﬁed from strain
SC5314 and cloned upstream of the green ﬂuorescent protein gamma variant (GFP)
coding sequence (33). Each reporter construct was then introduced into the wild-type
strain CAI4 (34). Consistent with the qRT-PCR data, in the absence of ﬂuconazole, GFP
expression was similar for either construct. While ﬂuconazole treatment increased
the GFP signal approximately eightfold in the strain carrying the longer promoter, no
increase was observed in the strain with the shorter ERG3 promoter (Fig. S4). This
further supports the existence of a promoter element, located between 582 and
1,000 bp upstream of the ERG3 open reading frame (ORF) that is required to activate
transcription in response to azole treatment. To determine whether ERG3 transcription
may be affected by changes in growth conditions, we examined the effects of tem-
perature (30°C, 35°C, and 37°C) as well as pH (pH 3, 4, 5, 6, and 7) using the PERG3-GFP
FIG 3 Loss of azole-inducible ERG3 transcription does not affect C. albicans stress tolerance or hyphal
growth. (A) C. albicans cell suspensions were prepared at 1  107 cells/ml, and serial 1:5 dilutions prepared
in sterile water. Cell suspensions were then applied to YPD agar plates or YPD agar supplemented with the
indicated concentrations of ﬂuconazole (Fluc), SDS, NaCl, or CaCl2 using a sterile multipronged applicator.
The plates were incubated at 30°C for 48 h and then imaged. (B) C. albicans strains were suspended at 1 
107 cells/ml in sterile water, and 2.5 l spotted onto either an M199 or 10% FBS agar plate. The resulting
colonies were imaged after 96-h incubation at 37°C. (C) The capacity to form bioﬁlms was also evaluated
in ﬂat-bottomed 96-well plates. Each C. albicans strain was grown in RPMI 1640 medium at 37°C for 24 h
and stained with crystal violet before bioﬁlm mass was quantiﬁed as OD570. Values are means plus standard
errors of the means (SEM) from four independent experiments. The bioﬁlm mass of each group was
compared using one-way ANOVA and Tukey’s multiple-comparison test. The value for the erg3Δ/Δ mutant
group was signiﬁcantly different (P  0.0001) from the values for the WT, shprERG3, and lnprERG3 groups
as indicated by the two asterisks.
ERG3, Azole Resistance, and C. albicans Pathogenicity ®
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reporter constructs. However, neither parameter had a signiﬁcant impact on GFP
expression from either the long or short promoters (less than twofold, data not shown).
In C. albicans, the Upc2p transcription factor enhances the expression of several
ergosterol biosynthetic genes in response to azole treatment, including ERG11 (35).
Although ERG3 appears to be a target of Upc2p in Saccharomyces cerevisiae (36), this
had not been conﬁrmed in C. albicans. To address this question, we introduced the
azole-responsive GFP reporter construct (with the longer promoter) into an upc2Δ/Δ
deletion strain. In the absence of ﬂuconazole, GFP expression was similar in the
upc2Δ/Δ mutant and wild-type strain backgrounds, indicating similar levels of basal
transcription (Fig. 4). Fluconazole treatment increased GFP expression about 10-fold in
the wild-type strain, but not in the upc2Δ/Δ mutant. These results conﬁrm that the
induction of ERG3 transcription that occurs in C. albicans upon azole treatment is
completely dependent upon the Upc2p transcription factor.
Using the program matrix-scan at the Regulatory Sequence Analysis Tool RSAT-
Fungi webserver (http://rsat-tagc.univ-mrs.fr/rsat/matrix-scan_form.cgi) (37), we searched
for motifs that may represent putative Upc2p-binding sites within the 5= UTR of ERG3.
A cis-regulatory element-enriched region (CRER) was identiﬁed between positions
751 to 373. Within this region, four motifs represent putative Upc2p-binding sites
(Fig. S5). Another element located at positions 379 to 373 (TCGTTTA) that coincides
with a putative Upc2-binding site resembles the classical sterol-responsive element
(SRE) TCGTATA, present in the 5= UTRs of UPC2 and several ergosterol biosynthetic
genes (38–40); hence, we deemed this sequence an “imperfect” SRE (iSRE) (Fig. S5). The
ERG3 promoter also contains two elements that match the TATA box consensus
sequence TATAWAWR (W means A or T, and R means A or G) (41); the ﬁrst element is
located at positions 679 to 672, and the second element is located at positions
343 to 336 (Fig. S5). Nonetheless, the role of each of the above elements in ERG3’s
transcriptional upregulation in response to the azoles has not yet been determined.
Loss of azole-inducible ERG3 transcription is sufﬁcient to eliminate “toxic” diol
production in ﬂuconazole-treated C. albicans. In order to compare levels of Erg3p
activity, we analyzed the composition of sterols extracted from both untreated and
ﬂuconazole-treated cultures of each strain. As expected, untreated wild-type and
lnprERG3 cells produced an abundance of ergosterol (Table 1). In contrast, the erg3/
FIG 4 Azole-inducible ERG3 transcription is dependent upon the Upc2p transcription factor. The GFP
coding sequence was cloned downstream of 1 kb of the ERG3 promoter sequence, and the resulting
construct introduced into C. albicans wild-type strain CAI4 (WT) or a upc2Δ/Δ mutant. The resulting
strains were grown in YNB broth in the presence or absence of 5 g/ml ﬂuconazole for 24 h at 35°C with
shaking, before GFP ﬂuorescence was quantiﬁed (excitation wavelength of 488 nm [9 nm bandpass];
emission wavelength of 507 nm [9 nm bandpass]). Fluorescence intensity was then normalized to the cell
density (OD600) and expressed relative to the DMSO control. The means  the standard deviations for
four biological replicates are shown. The relative ﬂuorescence of each treatment group was then
compared using a two-way ANOVA and Tukey’s multiple-comparison test, and the P values are indicated.
Luna-Tapia et al. ®
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mutant did not produce detectable levels of ergosterol under untreated conditions,
instead accumulating high levels of ergosta-7,22-dienol. The addition of ﬂuconazole
reduced ergosterol content in the wild-type and lnprERG3 strains by more than 25-fold
and induced the formation of signiﬁcant levels of 14-methylergosta-8,24(28)-dien-
3,6-diol (Table 2). However, erg3/ cells did not form the dysfunctional diol species
upon ﬂuconazole treatment. Interestingly, while the shprERG3 strain formed near
normal levels of ergosterol in the absence of drug (Table 1), it failed to produce
detectable levels of the sterol-diol species upon ﬂuconazole treatment (Table 2). The
capacity to produce ergosterol in the absence of drug explains the lack of stress and
hyphal growth phenotypes for the shprERG3 strain. The azole resistance of this strain
can also be explained by the absence of abnormal diols upon antifungal treatment.
TABLE 1 Sterol proﬁles of untreated C. albicans erg3Δ/Δ mutant and control strains
Sterol
Sterol contenta (%) (mean  SD) in strain:
WT erg3/ shprERG3 lnprERG3
Squalene 8.9  0.6 3.0  0.3 6.5  0.5 7.7  1.0
Unknown sterolb ND 0.2  0.0 ND ND
Ergosta-8,22-dienol ND 8.0  0.4 ND ND
Ergosta-8,22,24-trienol ND 0.8  0.0 ND ND
Ergosta-5,8,22,24(28)-tetraenol 1.3  0.1 ND 0.8  0.0 1.2  0.0
Ergosta-5,8,22-trienol 0.6  0.0 ND 0.3  0.0 0.6  0.1
Zymosterol 8.0  0.2 ND 5.1  0.4 5.7  0.5
Ergosterol 58.4  0.7 ND 43.1  0.5 58.4  2.8
Ergosta-7,22-dienol ND 35.9  0.5 5.8  0.5 1.3  0.4
Ergosta-5,7,22,24-tetraenol 1.8  0.1 ND 0.9  0.1 1.2  0.1
Ergosta-7,22,24(28)-trienol ND 0.5  0.1 ND ND
Fecosterol [E8,24(28)] 4.5  0.1 16.8  1.4 10.4  0.3 5.3  0.3
Ergosta-8-enol ND 2.7  1.8 1.0  0.0 0.5  0.1
14-Methylfecosterol ND 0.5  0.1 ND ND
Ergosta-5,7,24(28)-trienol 1.3  1.0 ND 1.2  0.5 2.2  0.8
4-Methylzymosterol ND 0.4  0.0 ND ND
Ergosta-5,7-dienol 4.2  0.2 ND 2.1  0.3 3.0  0.3
Episterol 5.1  0.1 24.1  1.4 18.0  0.3 8.9  0.4
Ergosta-7-enol 0.2  0.1 3.6  0.3 0.9  0.2 0.4  0.0
Lanosterol 4.1  0.3 2.0  0.2 2.7  0.3 2.7  0.2
4-Methylfecosterol ND 0.3  0.0 ND ND
4,4-Dimethylcholesta-8,24-dienol 1.4  0.0 0.5  0.1 0.7  0.0 0.8  0.1
Unknown sterolb ND 0.4  0.1 ND ND
Eburicol 0.2  0.0 0.3  0.0 0.2  0.0 0.2  0.0
¥(“ERG3 sterols”) 67.6  2.1 0.0  0.0 48.6  1.4 66.6  4.1
aThe content of sterols indicative of Erg3p activity is shown in boldface type. ND, not detected.
bSterols that have not been identiﬁed (the mass ion and/or fragmentation pattern was unclear).
TABLE 2 Sterol proﬁles of ﬂuconazole-treated C. albicans erg3Δ/Δ mutant and control
strains
Sterol
Sterol contenta (%) (mean  SD) in strain:
WT erg3/ shprERG3 lnprERG3
Ergosterol 2.0  0.2 ND 0.7  0.1 1.0  0.6
Ergosta-7,22-dienol ND 1.3  0.1 0.5  0.0 ND
4,14-Dimethylzymosterol 11.3  0.3 14.7  1.0 14.3  0.6 12.1  0.8
14-Methylfecosterol 4.5  0.2 1.7  0.2 2.3  0.1 2.5  0.1
4,4-Dimethyl-ergosta-8,14,24(28)-trienol 1.2  0.1 0.8  0.0 0.7  0.1 0.8  0.0
14-Methyl-ergosta-8,24(28)-dien-3-6-diol 2.7  0.5 ND ND 1.1  0.4
Lanosterol 41.6  0.3 33.0  0.6 33.6  0.9 36.0  0.3
14-Methyl-ergosta-trienolb 1.1  0.1 1.0  0.1 1.0  0.0 0.9  0.1
Eburicol 35.5  0.7 47.6  1.7 47.0  1.7 45.6  0.8
¥(“ERG3 sterols”) 4.7  0.7 0.0  0.0 0.7  0.1 2.2  0.9
aThe content of sterols indicative of Erg3p activity is shown in boldface text. ND, not detected.
bIn some cases (e.g., 14-methyl-ergosta-trienol), we cannot be certain of the arrangement of double bonds in
the sterol, but it is an ergosta type sterol with three double bonds and a 14-methyl group.
ERG3, Azole Resistance, and C. albicans Pathogenicity ®
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Loss of azole-inducible ERG3 transcription does not compromise C. albicans
pathogenicity, but it is insufﬁcient to confer ﬂuconazole resistance in a mouse
model of disseminated infection. It has been previously reported that deletion of
ERG3 in the SC5314 strain background reduces C. albicans virulence in the mouse
model of disseminated candidiasis (20, 21, 23). We therefore compared the pathoge-
nicity of our erg3/, shprERG3, and lnprERG3 strains to a wild-type control using the
same model. This conﬁrmed that our erg3/ strain is severely impaired in this model,
as it failed to cause mortality within 14 days of inoculation (Fig. 5A). In contrast, the
virulence of both the shprERG3 and lnprERG3 strains was indistinguishable from that of
the wild-type strain, with each causing 100% mortality. This further supports our earlier
conclusion that the ﬁtness and pathogenicity of the shprERG3 strain are not compro-
mised, despite its in vitro azole resistance. Interestingly, while the erg3/ deletion
strain did not cause mortality, it was able to persist within the mouse tissues to the end
of the experiment {(~2.03  1.32)  106 CFU/g [mean  standard error of the mean
(SEM)]; day 14 postinoculation}. However, the erg3Δ/Δ mutant showed defects in hypha
formation in this model of infection (Fig. S6).
To compare the in vivo susceptibility of these strains to ﬂuconazole, a second
experiment was conducted in which groups of mice (four mice in each group) were
inoculated intravenously with each strain and then either treated for 7 days with
ﬂuconazole (25 mg/kg of body weight) or sham treated with phosphate-buffered saline
(PBS) via daily intraperitoneal injections. Consistent with the previous experiment,
nearly all mice infected with the wild type, shprERG3, and lnprERG3 and treated with
FIG 5 The shprERG3 strain is virulent but susceptible to ﬂuconazole treatment in a mouse model of
disseminated candidiasis. (A) BALB/c mice (six mice in each group) were inoculated with ~5  105 CFU
of either the WT (GP1), erg3Δ/Δ, shprERG3, or lnprERG3 strain via lateral tail vein injection. The mice were
then monitored three times daily for 14 days, and those showing distress were humanely euthanized. The
survival of each group was compared using the log rank test (P  0.0051). (B) Groups of BALB/c mice
were inoculated with ~5  105 CFU of either WT (GP1), erg3Δ/Δ, shprERG3, or lnprERG3 strain as
described above and then split into two treatment groups (four mice in each group). One group was
treated with 25 mg/kg ﬂuconazole (Fluc), and another group was treated with vehicle alone (PBS) by
daily intraperitoneal injection starting 24 h after infection. Animals were monitored for 8 days, and the
survival of each group was compared using the log rank test (P  0.0001).
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PBS succumbed to infection, whereas those mice treated with ﬂuconazole all survived
to day 8 (Fig. 5B). Analysis of fungal colonization of the kidneys revealed that
ﬂuconazole-treated mice had only low levels of fungal colonization {(8.77  1.33) 
102 CFU/g [mean SEM] for the wild-type, (2.97 1.26) 103 CFU/g for shprERG3, and
(2.64 0.14) 102 CFU/g for lnprERG3}, indicating that all three strains are susceptible
to ﬂuconazole in this model. Thus, while the shprERG3 strain is resistant in vitro, it is
apparently susceptible to ﬂuconazole in the mouse model of disseminated infection.
The erg3/ deletion strain failed to cause lethality in either the PBS or ﬂuconazole
treatment groups. However, kidney CFU counts from mice surviving to day 8 were not
signiﬁcantly different between the groups treated with ﬂuconazole [(3.66  2.34) 
104 CFU/g] and PBS [(2.22 0.49) 105 CFU/g]. Thus, while the erg3/ strain is much
less virulent than the other three strains in the mouse model of disseminated infection,
the persistent levels of CFU in the kidney indicate that it is apparently much more
resistant to ﬂuconazole treatment.
Complete or partial loss of Erg3p activity is sufﬁcient to confer ﬂuconazole
resistance in a mouse model of vaginal candidiasis. Previous investigations of
Erg3p’s role in C. albicans pathogenicity and azole resistance have focused exclusively
on the disseminated model of infection (20, 21, 23). However, it is unknown whether
loss of Erg3p activity is sufﬁcient to impair C. albicans virulence or confer azole
resistance in other host niches, such as the mucosal membranes that are its primary
habitat. To test this, we inoculated estrogen-treated mice intravaginally with either
wild-type, erg3Δ/Δ, shprERG3, or lnprERG3 strains. Each group was then split into two
treatment groups, with half the mice treated with ﬂuconazole (50 mg/kg) via intraperi-
toneal injection on days 4 and 7 postinoculation, and the other half receiving PBS
vehicle alone. The levels of fungal colonization were then determined as CFU from
vaginal lavage ﬂuid obtained on days 7 and 10. All four strains were able to colonize the
PBS-treated mice to similar levels at both time points (Fig. 6A and B). Fluconazole
treatment signiﬁcantly reduced fungal colonization by both wild-type and lnprERG3
strains but had less impact in animals infected with the erg3Δ/Δ or shprERG3 strain
(Fig. 6A and B). This indicates that both erg3Δ/Δ and shprERG3 strains are not only
proﬁcient at colonizing the mouse vagina but also have reduced susceptibility to
ﬂuconazole treatment at this site.
Smears from vaginal lavage ﬂuid samples were also made on days 7 and 10 to
compare the levels of polymorphonuclear leukocyte (PMN) inﬁltration, as high levels of
PMN inﬂux have been associated with symptomatology (42). Seven days postinocula-
tion, mice infected with the erg3/ mutant had only a slight reduction in PMN counts
compared to the other three strains, further supporting that the mutant has no major
virulence defect in this model of infection (Fig. 6C). On day 7, the ﬂuconazole treatment
groups had reduced PMN inﬂux in animals infected with the wild-type, shprERG3, and
lnprERG3 strains compared to the untreated groups. In contrast, ﬂuconazole had no
impact on PMN inﬂux in animals infected with the erg3/ mutant (Fig. 6C). By day 10,
only mice infected with the wild-type strain had a statistically signiﬁcant reduction in
PMN inﬂux in the treated versus untreated groups (Fig. 6D). Similar levels of PMNs were
observed in the treated and untreated animals infected with either the erg3/ or
shprERG3 strain, indicating little or no beneﬁt to treatment. For mice infected with the
lnprERG3 strain, there was a trend toward reduced PMN inﬂux in the ﬂuconazole-
treated group; however, this was not statistically signiﬁcant. Finally, the hyphae ob-
served in vaginal lavage ﬂuid from mice infected with the erg3/ mutant were
indistinguishable from hyphae formed by the other three strains in this model (Fig. S7).
Thus, the erg3/ mutant is not deﬁcient in hyphal growth at this mucosal site. These
ﬁndings indicate that the erg3Δ/Δ mutant has no colonization defect and is able to
induce pathology in the mouse model of vaginal candidiasis. Furthermore, in contrast
to the wild type, the capacity of the erg3Δ/Δ mutant to induce pathology is not
compromised by ﬂuconazole treatment.
ERG3, Azole Resistance, and C. albicans Pathogenicity ®
May/June 2018 Volume 9 Issue 3 e00225-18 mbio.asm.org 9
 
m
bio.asm
.org
 o
n
 June 13, 2018 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
DISCUSSION
In vitro selection studies with several fungal species have demonstrated that azole
resistance frequently results from mutations that inactivate the sterol C-5-desaturase en-
coded by ERG3 (15, 43, 44). However, relatively few Erg3p-deﬁcient mutants have been
identiﬁed among azole-resistant clinical isolates of C. albicans (5, 16–18), which instead
seem to favor mechanisms involving alterations of the target protein’s amino acid se-
quence, increased target protein expression, and/or elevated expression of drug efﬂux
pumps (6–10). This is somewhat surprising, as the acquisition of clinically relevant levels of
azole resistance usually requires some combination of these mechanisms, and is thought to
be a stepwise process (7, 11–13). In contrast, inactivation of Erg3p can offer a single step
mechanism to complete azole resistance. Several factors may help explain the apparent
disparity between the high frequency with which azole-resistant erg3 mutants can be
selected in vitro and their infrequent occurrence in the clinical setting.
First, the ploidy of the fungal species in question is likely to affect the frequency with
which erg3 mutants arise, as erg3 loss-of-function mutations are recessive (15). As such,
while azole-resistant erg3 mutants can be readily selected in a haploid species such as S.
cerevisiae (15, 44–46), they are expected to occur less frequently in a constitutively diploid
species such as C. albicans, as inactivation of both ERG3 alleles is necessary to increase MICs.
This would require either two independently occurring mutations in either allele, or
mutation in one allele followed by a gene conversion event. In contrast, activating muta-
tions in the Upc2p transcription factor, which controls expression of the target enzyme
FIG 6 The erg3Δ/Δ and shprERG3 C. albicans strains are resistant to ﬂuconazole treatment in a mouse model of vaginal candidiasis. Four groups of 16
estrogen-treated female C57BL/6 mice were each inoculated intravaginally with either the WT (GP1), erg3Δ/Δ mutant, shprERG3, or lnprERG3 strain of
C. albicans. Each group was then split into two treatment groups (n  8). One group was treated with 50 mg/kg of ﬂuconazole, and the second group was
treated with vehicle alone (PBS) via intraperitoneal injection on days 4 and 7 postinfection. The levels of fungal colonization were compared 7 days (A) and
10 days (B) postinfection by quantifying CFU from vaginal lavage ﬂuid. Polymorphonuclear leukocyte (PMN) inﬁltration into the vaginal mucosa was also
compared from smears of lavage ﬂuid taken on day 7 (C) or 10 (D) and stained by the Papanicolau technique. The number of PMNs were then determined by
counting the number in ﬁve nonadjacent ﬁelds using a light microscope with a 40 objective. The mean  standard error of the mean (SEM) are shown for
all panels. Pairwise comparisons between treatment groups were performed using one-way ANOVA analysis with Kruskal-Wallis test.
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Erg11p, or those controlling expression of the Candida drug resistance (CDR)- and multi-
drug resistance (MDR)-type drug efﬂux pumps (Tac1p and Mrr1p), can be either semidom-
inant or fully dominant (13, 47–49). Nonetheless, in vitro selection of Candida dubliniensis,
a diploid species, with itraconazole primarily selects for Erg3p-deﬁcient resistant mutants
(43). Thus, ploidy alone does not satisfactorily account for the low frequency with which
azole-resistant erg3 mutants are isolated in the clinical setting.
A second factor may be the concentration of drug to which the fungus is exposed.
Anderson et al. reported that in vitro exposure of S. cerevisiae isolates to high doses of
ﬂuconazole primarily selects for erg3mutants, while progressive selection with stepwise
increases in ﬂuconazole concentration favors resistance mechanisms that involve ele-
vated expression of drug efﬂux pumps (15). As such, it is conceivable that patient
dosing and drug availability at the site of infection are important determinants of the
adaptive mechanisms that arise.
A third, possible explanation for the infrequent isolation of erg3 mutants in the
clinical setting may be the associated ﬁtness costs. It is clear from our data, as well as
several other studies, that while complete loss of Erg3p activity leads to in vitro azole
resistance, it concurrently causes several phenotypic abnormalities. These abnormali-
ties include hypersensitivity to various physiological stresses, as well as deﬁciencies in
hyphal growth under at least some culture conditions. The resulting loss of pathogenic
ﬁtness may oppose or disfavor the selection of erg3 mutants in patients receiving azole
treatment. While the alternative sterol species that accumulate in erg3 null mutants are
sufﬁcient to support propagation in lab culture, they may be less compatible with
fungal survival, proliferation, or invasiveness during infection of the mammalian host.
This is supported by several studies that have shown that erg3 mutants isolated from
the clinical setting and lab-engineered erg3/ strains are less virulent than wild-type
isolates in murine models of disseminated infection (18, 20, 23). Interestingly, Vale-Silva
et al. reported an azole-resistant C. albicans clinical isolate with an erg3 null mutation,
which is apparently virulent, and had no obvious defects in stress tolerance or hyphal
growth (17). The authors suggest that this isolate may harbor compensatory mutations
that counteract the effects of Erg3p inactivation. The nature of the compensatory
mechanism(s) and the frequency with which they can coincide with erg3 inactivating
mutations are unknown. Nonetheless, the weight of evidence, including the in vitro
data presented herein, suggests that in the absence of compensatory mechanisms or
mutations, complete loss of ERG3 function is detrimental to C. albicans pathogenic
ﬁtness. This notion was only partially supported by our in vivo data, which revealed that
the erg3/ mutant has niche-speciﬁc defects in pathogenicity.
In both disseminated and vaginal models of infection, wild-type C. albicans is
pathogenic but susceptible to azole treatment. In contrast, the erg3/ mutant has
severely attenuated virulence in the mouse model of disseminated candidiasis but is
proﬁcient at colonizing and capable of inducing pathology in the vaginal model of
infection. Thus, the ﬁtness defects incurred upon Erg3p inactivation are apparently of
greater consequence during disseminated infection than mucosal propagation and/or
infection. This may reﬂect the fact that C. albicans is highly adapted for a commensal
lifestyle upon mucosal surfaces and typically only disseminates in a highly debilitated
mammalian host. Our previous ﬁnding that C. albicans erg2/ and erg24/ mutants
(lacking C-8 sterol isomerase and C-14 sterol reductase, respectively) are avirulent in the
mouse model of disseminated infection but readily colonize the mouse vagina (26)
further supports the notion that mucosal environments may be more permissive of
alterations in the ergosterol biosynthetic pathway than deeper infection sites. Either
way, the deletion mutant is relatively resistant to ﬂuconazole treatment in both models
of infection. As such, while the erg3/ mutant has niche-speciﬁc virulence defects, it
is more azole-resistant than the wild type is at both mucosal and disseminated sites of
infection (Table 3).
Our results with the shprERG3 strain indicate that complete loss of Erg3p activity is
not necessary to confer azole resistance. Speciﬁcally, the loss of azole-inducible tran-
scription of ERG3 apparently confers ﬂuconazole resistance in vitro without compro-
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mising C. albicans pathogenic ﬁtness. Like the wild type, the shprERG3 strain was
pathogenic in both models of infection and susceptible to azole treatment in the
disseminated model. However, the shprERG3 strain was more resistant to ﬂuconazole
treatment in the vaginal model than the wild type, and therefore exhibits niche-speciﬁc
azole resistance (Table 3). These ﬁndings imply that the level of expression and speciﬁc
activity of Erg3p directly impact C. albicans pathogenicity and susceptibility to azole
therapy. Moreover, titrating Erg3p expression/activity has niche-speciﬁc consequences
upon these vitally important characteristics.
The fourth possible explanation for the dearth of Erg3p-deﬁcient mutants in the
clinical setting may be that many are overlooked, as C-5 desaturase activity is not
routinely examined. Point mutations and polymorphisms within ERG3 can be readily
detected through sequence analysis, and isolates bearing nonsense mutations—result-
ing in a truncated (nonfunctional) polypeptide are easily identiﬁed. However, the
consequences of missense mutations or polymorphisms within the 5= and 3= noncod-
ing regions upon Erg3p expression, speciﬁc activity, or azole susceptibility are rarely
investigated. A detailed biochemical analysis of cellular sterol content is required to
conﬁrm deﬁciencies in C-5 desaturase activity—an analysis that is not routinely per-
formed on all azole-resistant isolates. If this analysis is performed, isolates with a
substantive reduction in C-5 sterol desaturase activity can be detected as having
signiﬁcantly reduced ergosterol content (or its complete absence) and an accumulation
of ergosta-7,22-dienol. Accordingly, to date, most reports have focused upon describ-
ing clinical isolates with mutations that completely inactivate the ERG3 gene. However,
isolates with only a partial reduction in Erg3p activity will have more subtle shifts in
sterol proﬁles that may not be as obvious. This is important, as the results described
herein suggest relatively small adjustments to ERG3 transcription may be sufﬁcient to
induce azole resistance in C. albicans—at least within some host niches. The Kelly lab
has previously shown that many of the azole-resistant S. cerevisiae erg3 mutants they
selected in vitro are in fact “leaky” mutants that only partially impair Erg3p catalytic
activity (45). Through thorough analysis of sterol proﬁles, at least two leaky erg3
mutants were also identiﬁed among a panel of azole-resistant clinical C. albicans
isolates (16). Such mutations permit the production of at least some ergosterol but are
also sufﬁcient to induce full azole resistance in vitro (16). Notably, the two leaky erg3
C. albicans mutants show phenotypic proﬁles similar to the proﬁle of the shprERG3
strain reported here, i.e., full azole resistance in vitro but normal hyphal growth and
stress tolerance (see Fig. S7 in the supplemental material). Our ﬁndings beg a series of
important questions: To what degree does Erg3p activity need to be suppressed to
induce azole resistance? To what degree can Erg3p activity be suppressed before the
ﬁtness or pathogenicity of C. albicans is compromised? Are there levels of Erg3p activity
that can support full azole resistance without compromising C. albicans pathogenicity?
Do the Erg3p activity levels required to support C. albicans pathogenicity and/or
determine azole susceptibility/resistance vary between different host niches (e.g., oral
versus vaginal versus disseminated) or according to host immune status? Our results
also raise the question of whether, and how, altered transcriptional regulation might
TABLE 3 Summary of pathogenicity and azole susceptibility results in the mouse models
of vaginal and disseminated candidiasis
Strain
Summary of resultsa
Vaginal infection Disseminated infection
Pathogenicity Azole resistance Pathogenicity Azole resistance
WT ***** * ***** *
erg3Δ/Δ ***** ***** ** ***
shprERG3 ***** ***** ***** *
lnprERG3 ***** ** ***** *
aEach phenotype is scored on a scale of 1 to 5 with * indicating little or no pathogenicity/azole resistance
and ***** indicating full pathogenicity/azole resistance.
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confer Erg3p-dependent clinical azole resistance that may not be apparent in vitro
using the standard CLSI MIC assay. Similarly, are there host relevant factors that
impinge upon the regulation of Erg3p expression or activity? In this regard, using the
PERG3-GFP, we found that -estradiol (1.25 to 10 g/ml), which was used in the vaginal
model, did not affect transcription from the ERG3 promoter in the presence or absence
of ﬂuconazole (not shown). Finally, and perhaps most importantly, given the almost
exclusive focus thus far on erg3 null mutants—might the role of Erg3p as a determinant
of C. albicans azole resistance have been grossly underestimated?
In summary, we have demonstrated that relatively minor adjustments in the regu-
lation of ERG3 transcription are sufﬁcient to induce azole resistance without compro-
mising C. albicans hyphal growth or stress tolerance. Furthermore, even complete loss
of Erg3p activity does not compromise C. albicans pathogenic ﬁtness in a murine model
of vaginal candidiasis. On the basis of these results and those presented elsewhere (16),
we propose that a more thorough investigation of the role of the ERG3 gene as a
determinant of azole susceptibility in the clinical setting is warranted. These investiga-
tions should not only seek to identify erg3 null mutants but also consider the effects of
variation in ERG3 transcription, protein expression, and missense mutations on the
catalytic activity of Erg3p. Furthermore, the consequences of altered Erg3p activity
upon fungal pathogenicity should be simultaneously examined.
MATERIALS AND METHODS
Growth and media conditions. All C. albicans strains were routinely grown on yeast extract-
peptone-dextrose (YPD) agar plates or in liquid medium at 30°C and supplemented with uridine
(50 g/ml) when necessary. Transformant selection was carried out on minimal YNB medium (6.75 g/liter
yeast nitrogen base without amino acids, 2% dextrose, 2% Bacto agar), supplemented with the appro-
priate auxotrophic requirements as described for S. cerevisiae (50) or uridine at 50 g/ml. All C. albicans
strains were stored frozen at 80°C in 20% glycerol.
For sterol extraction, strains were grown overnight in YNB, and 100 l of a solution with 1 
106 cells/ml were used to inoculate a ﬁnal volume of 10 ml YNB broth plus 5 g/ml ﬂuconazole or 0.5%
dimethyl sulfoxide (DMSO) (minus ﬂuconazole control) to give a starting concentration of 1  104 cells/
ml. These cultures were grown at 35°C for 24 h with shaking at 160 rpm. All strains were grown in
triplicate.
For RNA extraction, 1 104 cells/ml were inoculated in 5 ml YPD and grown at 37°C with shaking for
24 h in the presence of 4 g/ml of ﬂuconazole or 0.5% DMSO. All strains were grown in triplicate.
Plasmid construction. Plasmid pLUX (28), was kindly provided by William Fonzi (Georgetown
University). Plasmid pKE1 (51) was previously described. All oligonucleotides used in this study are listed
in Table S1 in the supplemental material.
The ERG3 ORF with 5= and 3= UTR sequences was ampliﬁed from SC5314 genomic DNA (gDNA) with
Hi-Fi Platinum Taq (Invitrogen) and primer pairs ERG3AMPF-StuI plus ERG3AMPR-SacI or ERG3AMPF2-StuI
plus ERG3AMPR-SacI, and cloned between the StuI and SacI restriction sites of pLUX to produce plasmids
pLUX-shprERG3 (containing ~582 bp of the ERG3 promoter) and pLUX-lnprERG3 (containing 1 kb of the
ERG3 promoter), respectively.
Construction of the reporter plasmids for transcriptional analysis, plnERG3prGFP and
pshERG3prGFP, was performed as follows. Different lengths of the ERG3 promoter were ampliﬁed from
SC5314 gDNA with primer pairs ERG3lngpF-KpnI plus ERG3prR-SalI (1,000 bp upstream of the start
codon) or ERG3shrpF-KpnI plus ERG3prR-SalI (582 bp upstream of the start codon). These promoter
fragments were then cloned between the KpnI and SalI sites of pKE1 in place of the ACT1 promoter. The
GFP coding sequence was then ampliﬁed using primer pair GFPAMPF-SalI plus GFPAMPR-MluI and
cloned downstream of the ERG3 promoter between SalI and MluI sites.
C. albicans strain construction. Strains used in this study are listed in Table S2. Gene deletion strains
were constructed by the PCR-based approach of Wilson et al. (27), using the ura3/ his1/ arg4/
strain BWP17 (kindly provided by Aaron Mitchell, Carnegie Mellon University).
ERG3 deletion cassettes were ampliﬁed by PCR with primer pair ERG3DISF plus ERG3DISR, using
pRS-ARG4SpeI or pGEM-HIS1 (27) as the template. Each ERG3 allele was sequentially deleted from strain
BWP17 using ARG4 and HIS1 markers to generate erg3/ ura3/ gene deletion mutants. Correct
integration of deletion cassettes was conﬁrmed at each step by PCR with the following primer sets:
ARG4INTF2 plus ERG3AMPR-SacI and ARG4INTR2 plus ERG3AMPF-SacI (ARG4 integration) or HIS1INTF2
plus ERG3AMPR-SacI and HIS1INTR2 plus ERG3AMPF-SacI (HIS1 integration). The lack of an intact ERG3
allele was conﬁrmed using primer pair ERG3DETF and ERG3DETR.
For construction of the C. albicans upc2Δ/Δ ura3Δ/Δ mutant, each UPC2 allele was sequentially
deleted from strain BWP17 using the ARG4 and HIS1 markers. Deletion cassettes were ampliﬁed with
primer pairs UPC2DISF plus UPC2DISR, using pRS-ARG4SpeI or pGEM-HIS1 (27) as the template. Correct
integration of deletion cassettes was conﬁrmed by PCR with the following primer sets: UPC2AMPF-KpnI
plus ARG4INTR2 and UPC2AMPR-SacI plus ARG4INTF2 (ARG4 integration), or UPC2AMPF-KpnI plus
ERG3, Azole Resistance, and C. albicans Pathogenicity ®
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HIS1INTR2 and UPC2AMPR-SacI plus HIS1INTF2 (HIS1 integration). The absence of an intact UPC2 allele
was conﬁrmed using primer pair UPC2SEQF1 and UPC2SEQR3.
For the construction of the strains used in the GFP reporter assays, plasmids plnERG3prGFP and
pshERG3prGFP were linearized with NheI and transformed into wild-type CAI4 and upc2/ ura3/
strains.
Stress resistance and hyphal growth assays. For stress resistance analysis, C. albicans was grown
overnight in YPD at 30°C. Cells were washed in sterile deionized water, cell density was adjusted to
107 cells/ml, and 1:5 serial dilutions were performed in a 96-well plate. Cells were then applied to agar
plates using a sterile multipronged applicator. Resistance to different stresses was determined on YPD
agar containing 8 g/ml of ﬂuconazole, 0.05% SDS, 1.5 M NaCl, or 500 mM CaCl2, with incubation at 30°C
during 48 h.
For hyphal growth analysis, 2.5 l from a cell suspension with 107 cells/ml was spotted on M199 agar
or 10% FBS (fetal bovine serum) agar plates, followed by incubation for 96 h at 37°C.
Quantiﬁcation of bioﬁlm biomass. Each C. albicans strain was grown overnight in YPD broth at 37°C
with shaking at 200 rpm. Each culture was then washed two times in sterile phosphate-buffered saline
(PBS), cell density was adjusted to 1  106 per ml in RPMI 1640 medium, and 200 l was dispensed into
each well of a ﬂat-bottomed, 96-well plate (six wells per strain). After incubation at 37°C for 24 h, the
plate was rinsed three times with sterile PBS and then stained with 0.01% crystal violet (MP Biomedicals)
for 15 min. The plate was again rinsed three times with sterile water, and bioﬁlms were eluted with 95%
ethanol (200 l/well). One hundred twenty-ﬁve microliters of resolubilized dye was transferred to a new
microtiter plate, and the optical density at 570 nm (OD570) was measured using a microplate reader. Four
independent experiments were performed.
Antifungal susceptibility testing. Antifungal susceptibility testing of all the strains included in this
study was performed by using the broth microdilution method described in the CLSI document M27-A3
(30) in a 96-well plate format. All drugs for susceptibility testing used in this study were diluted in DMSO
in twofold dilutions at 200 times the ﬁnal concentration. Fluconazole (Sigma-Aldrich) concentrations
tested ranged from 64 g/ml to 0.0313 g/ml. RPMI 1640 medium (Sigma-Aldrich) was prepared
according to the CLSI document. The medium was buffered with 0.165 M morpholinepropanesulfonic
acid (MOPS), and its pH was adjusted using NaOH and HCl. Cell inoculum was ~1  103 cells per well.
Plates were incubated without shaking at 35°C for 24 or 48 h. The content of each well was carefully
resuspended by pipetting up and down before OD600 was measured using a Cytation 5 cell imaging
multimode reader (Bio-Tek Instruments, Inc.).
Sterol extraction and quantitation. Nonsaponiﬁable lipids were extracted using alcoholic KOH as
reported previously (52). Samples were dried in a vacuum centrifuge (Heto) and derivatized by the
addition of 100 l of 90% N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA)–10% trimethylsilyl (TMS)
(Sigma), 200 l of anhydrous pyridine (Sigma), and heating for 2 h at 80°C. TMS-derivatized sterols were
analyzed and identiﬁed using gas chromatography-mass spectrometry (GC-MS) (Thermo 1300 GC
coupled to a Thermo ISQ mass spectrometer; Thermo Scientiﬁc) with reference to retention times and
fragmentation spectra for known standards. GC-MS data ﬁles were analyzed using Xcalibur software
(Thermo Scientiﬁc) to determine sterol proﬁles for all isolates and for integrated peak areas. Percentages
of total sterols are given as the mean for three replicates.
RNA extraction. Cells were collected by centrifugation at 3,500 rpm for 5 min. Supernatant was poured
off, and cells pellets were stored at 80°C. RNA was extracted from the cell pellets using the hot phenol
method of Schmitt et al. (53). RNA pellets were eluted in 20 l of nuclease-free water, and quantity and purity
were determined spectrophotometrically by measuring absorbance at 260 nm and 280 nm.
Quantitative RT-PCR (qRT-PCR). RNA concentrations were adjusted to 1 g, and aliquots were
treated with DNase I as indicated by the manufacturer (Thermo Scientiﬁc). cDNA was synthesized using
the Verso cDNA synthesis kit (Thermo Scientiﬁc) with random hexamers according to the manufacturer’s
instructions. Quantitative PCR was performed with primer pairs that amplify 100 bp of the ACT1
(ACT1FWDS2 plus ACT1REVS2) or ERG3 (ERG3qPCR_F2 plus ERG3qPCR_R2) (Table S1) coding sequences
using the Maxima SYBR green/ROX quantitative PCR (qPCR) master mix (2) (Thermo Scientiﬁc) as
indicated by the manufacturer. Reactions were completed in a 7500 real-time PCR system (Applied
Biosystems). Expression levels of ERG3 were compared to those of ACT1 (normalizing gene) using the ΔCT
method as described previously (54).
GFP reporter assays. C. albicans strains expressing GFP from the ERG3 promoter were grown
overnight in YPD at 30°C, washed, and subcultured into 10 ml YNB at 1  106 cells/ml in the presence
of 5 g/ml ﬂuconazole or 0.5% DMSO, and then incubated at 35°C for 24 h with shaking. Cells were
pelleted and transferred to a round-bottomed 96-well plate, and GFP ﬂuorescence intensity was
quantiﬁed using a Cytation 5 cell imaging multimode reader (Bio-Tek Instruments, Inc.) with excitation
at 488 nm (9 nm bandwidth) and emission at 507 nm (9 nm bandwidth). Growth was determined by
measuring OD600 for normalization of the ﬂuorescence signal.
Ethics statement. The animals used in this study were housed in American Association for Accred-
itation of Laboratory Animal Care (AAALAC)-approved facilities at the University of Tennessee Health
Science Center (UTHSC). The Institutional Animal Care and Use Committee (IACUC) at UTHSC approved
use of all animals and procedures (IACUC protocol numbers 15-081 and 16-156). Mice were given
standard rodent chow and water ad libitum. Mice were monitored daily for signs of distress, including
noticeable weight loss, lethargy, and body condition score. The IACUC at UTHSC uses the Public Health
Service (PHS) Policy on Humane Care and Use of Laboratory Animals (55) and the Guide for the Care and
Use of Laboratory Animals (56) as a basis for establishing and maintaining an institutional program for
activities involving animals. To ensure high standards for animal welfare, the IACUC at UTHSC remains
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compliant with all applicable provisions of the Animal Welfare Act (AWAR) (57), guidance from the Ofﬁce
of Laboratory Animal Welfare (OLAW), and the American Veterinary Medical Association Guidelines on
Euthanasia (58).
Mouse model of vaginal candidiasis. C57BL/6 mice were administered 0.1 mg of estrogen
(-estradiol 17-valerate; Sigma) dissolved in 0.1 ml sesame oil subcutaneously 72 h prior to inoculation
with C. albicans. Estrogen injections were administered weekly thereafter. Stationary-phase cultures of
C. albicans isolates were washed three times in sterile, endotoxin-free PBS and resuspended in PBS at
2.5  108 cells/ml. Estrogen-treated mice (eight mice in each experimental group) were then inoculated
intravaginally with 20 l of the cell suspension (ﬁnal inoculum, 5  106 cells). Mice were monitored daily
for signs of distress, including noticeable weight loss and lethargy. Fluconazole treatment was admin-
istered at 50 mg/kg via intraperitoneal injection on days 4 and 7 postinoculation (p.i.). Vaginal lavage was
performed on day 7 and 10 p.i., and fungal colonization was quantiﬁed as CFU by plating serial dilutions
of the lavage ﬂuid onto YPD agar plates containing 50 g/ml of chloramphenicol. PMN counts within the
lavage ﬂuid samples were also enumerated as an indicator of inﬂammation. Smears of lavage ﬂuid
samples were stained by the Papanicolau technique, and the number of PMNs in ﬁve nonadjacent ﬁelds
was counted by using a light microscope with a 40 objective.
Mouse model of disseminated candidiasis. C. albicans strains were grown overnight in YPD
cultures at 30°C with shaking. Stationary-phase cultures of C. albicans strains were washed twice in sterile,
endotoxin-free PBS and resuspended in PBS. BALB/c mice were inoculated via tail vein injection with
~5 105 cells in 100 l of cell suspension. Viable-cell counts of each inoculum were conﬁrmed by plating
appropriate dilutions onto YPD agar plates and counting the colonies formed after 48 h.
Pathogenesis experiment. Groups of six animals per strain were infected and monitored for 14 days
p.i., and those showing signs of distress were humanely sacriﬁced. Surviving animals by day 14 p.i. were
euthanized. The kidneys from each mouse were extracted, weighed, and homogenized in PBS. Serial
dilutions of kidney homogenate were plated on YPD agar plates containing 50 g/ml of chloramphen-
icol. The number of CFU/gram of kidney tissue was determined from the number of colonies on the
plates after 48 h.
In vivo ﬂuconazole treatment experiment. Groups of eight animals per strain were inoculated via
tail vein injection with 100 l of cell suspension. After 24 h p.i., each group was split into two groups of
four animals each. Either group was treated intraperitoneally with 200 l of 25 mg/kg/day of ﬂuconazole
or with vehicle alone (PBS plus 1% DMSO) daily for 6 days (until day 7 p.i.). Mice were monitored daily,
and those showing distress were euthanized. Kidneys were removed from each mouse at the time of
death, weighed, and homogenized in PBS, and their fungal burdens were determined as described earlier
in this article. On day 8 p.i., all surviving animals were sacriﬁced, their kidneys were removed, and their
fungal burdens were determined as explained previously.
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